SYMKEVI

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug SYMKEVI contains a combination of these active pharmaceutical ingredients (APIs):

1	Tezacaftor UNII 8RW88Y506K - TEZACAFTOR
2	Ivacaftor UNII 1Y740ILL1Z - IVACAFTOR
	Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations with reduced channel-open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance).
	Read more about Ivacaftor

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R07AX31		R Respiratory system → R07 Other respiratory system products → R07A Other respiratory system products → R07AX Other respiratory system products
Discover more medicines within R07AX31

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1782390, 1834028
ES	Centro de información online de medicamentos de la AEMPS	1181306001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	396604
FR	Base de données publique des médicaments	62984481, 66848831
GB	Medicines & Healthcare Products Regulatory Agency	367455, 391985
IE	Health Products Regulatory Authority	88845, 89045
IT	Agenzia del Farmaco	047307018, 047307020
LT	Valstybinė vaistų kontrolės tarnyba	1086559, 1091497
NL	Z-Index G-Standaard, PRK	197424
PL	Rejestru Produktów Leczniczych	100413101, 100446589
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67229001, W67230001